PT - JOURNAL ARTICLE AU - Preethi Ramachandran AU - Abhilash Perisetti AU - Mahesh Gajendran AU - Farla Jean-Louis AU - Pardeep Bansal AU - Alok Kumar Dwivedi AU - Hemant Goyal TI - Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19 AID - 10.1101/2020.07.12.20151084 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.12.20151084 4099 - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151084.short 4100 - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151084.full AB - Background and Aim Gastric acid has shown to neutralize many viruses. The working receptor of SARS-CoV-2 is angiotensin-converting enzyme-2 (ACE-2), which has shown to be omnipresent in the gastrointestinal tract. There is a theoretical concern that SARS-CoV-2 can escape the neutralization by gastric acid because of hypochlorhydria caused by the use of proton pump inhibitors (PPI) and can predispose the patients for severe COVID-19.Methods We studied the association between prehospitalization PPI use and clinical outcomes among hospitalized COVID-19 patients.Results In our study, 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.5 times higher risk of mechanical ventilation. This relationship existed even after adjusting for confounding variables.Conclusion These results warrant further investigation in prospective studies to evaluate if PPI-induced hypochlorhydria is associated with worse outcomes, including mortality because of the omnipresence of ACE-2 in the gastrointestinal tract.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board (Protocol 20-12).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available